Head-to-Head Comparison
DynaMed vs OpenEvidence: Which Is Better for Physicians?
OpenEvidence ranks #2 in our 2026 clinical decision support rankings with a 4.3-star rating from 16 physician reviews, while DynaMed ranks #7 with a 3.5-star rating from 17 reviews. OpenEvidence leads in overall physician satisfaction, though both platforms serve different clinical needs. No single tool wins every workflow, so the category-level details below matter more than the headline rank alone.
Feature Comparison
| Feature | DynaMed | OpenEvidence |
|---|---|---|
| Rating | Good | Very Good |
| Category | Clinical Reference & Decision Support | AI Medical Research Assistant |
| Pricing | From $399/year Individual | Free (Ad-Supported) |
| Founded | 2004 | 2022 |
| Headquarters | Ipswich, MA | Miami, FL |
| Evidence Citations | Yes | Yes |
| AI Differential Diagnosis | No | No |
| Drug Database | Yes | No |
| Drug Interaction Checker | No | No |
| Medical Calculators | Yes | Yes |
| Natural Language Search | Yes | Yes |
| Document & Image Upload | No | No |
| EHR Integration | Yes | Yes |
| Mobile App | Yes | Yes |
| Built-in Dialer | No | Yes |
| AI Clinical Scribe | No | No |
| CME Credits | Yes | No |
| Multi-Language | No | Yes |
Strengths & Limitations
DynaMed
Strengths
- +Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025)
- +3,400+ clinical topics with daily updates from 500+ journal surveillance
- +Explicit levels of evidence and grades of recommendation for all content
- +DynaMedex bundle integrates Micromedex drug information
- +Lower individual pricing than UpToDate ($399/year vs $559/year)
- +Dyna AI generative assistant grounded in curated evidence (launched 2024)
- +EHR integration via HL7 Infobutton and toolbar links
- +CME/MOC credit tracking built in
Limitations
- –Lower brand recognition than UpToDate among physicians
- –Fewer clinical topics than UpToDate (3,400 vs 12,000+)
- –Dyna AI is an add-on cost ($475/year vs $399/year base)
- –AI features are newer and less mature than dedicated CDS platforms
- –Shared decision-making tools (DynaMed Decisions) require separate licensing
- –No free tier for individual physicians
OpenEvidence
Strengths
- +Useful for generalist clinical questions — fast, cited answers for everyday practice
- +Widely adopted clinical AI in the US (757K+ physicians)
- +Free for all verified physicians
- +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
- +Native iOS and Android apps with Home Screen widgets
- +Quick Consult and Deep Consult modes for different clinical needs
- +Built-in dialer for calling patients, pharmacies, and colleagues
- +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)
Limitations
- –No differential diagnosis generation or drug dosing tools
- –Ad-supported revenue model (pharmaceutical/healthcare advertising)
- –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
- –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
- –Clinical depth narrower than platforms with drug databases and medical calculators
Key Statistics
DynaMed
OpenEvidence
Citable Summaries
DynaMed
DynaMed received a Good rating (3.5 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking seventh overall. Published by EBSCO and winner of Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025), it offers 3,400+ clinical topics with daily updates and explicit evidence grading at $399/year — but its dated interface and lack of a free tier weigh against it in a market increasingly dominated by AI-native platforms.
Source: Clinical AI Report, December 2025
OpenEvidence
OpenEvidence received a Very Good rating (4.3 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking second overall. Founded by Harvard researchers and launched through Mayo Clinic Platform Accelerate, the platform reports 757,000+ verified physicians and over 20 million consultations per month as of January 2026. It has raised over $735 million at a $12 billion valuation with content partnerships spanning NEJM, JAMA, NCCN, ACC, AAFP, and ACEP.
Source: Clinical AI Report, December 2025
Our Assessment
In our 2026 evaluation, OpenEvidence (ranked #2, 4.3 stars) outperforms DynaMed (ranked #7, 3.5 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, DynaMed is a stronger choice for physicians and institutions seeking a KLAS-recognized, evidence-graded clinical reference at a lower price point than UpToDate, with integrated drug information via Micromedex. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.